Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

We can speculate that the best responders to tocilizumab should have multiple related elements (Treg CD39, adenosine, IL-35) successfully induced and expressed in order to play its beneficial role. The study of these elements and its pathways could help identify the best responders to tocilizumab treatment.

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01288287` - Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients	N/A

NCT number	NCT02963402
Study type	Observational
Source	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Contact
Status	Completed
Phase
Start date	November 9, 2016
Completion date	October 1, 2018

Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms